- Home
- NEE vs GILD Comparison
NEE vs GILD Comparison
Compare NEE & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEE
- GILD
- Stock Information
- Founded
- NEE 1925
- GILD 1987
- Country
- NEE United States
- GILD United States
- Employees
- NEE N/A
- GILD N/A
- Industry
- NEE Electric Utilities: Central
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEE Utilities
- GILD Health Care
- Exchange
- NEE Nasdaq
- GILD Nasdaq
- Market Cap
- NEE 155.3B
- GILD 139.6B
- IPO Year
- NEE N/A
- GILD 1992
- Fundamental
- Price
- NEE $70.78
- GILD $113.62
- Analyst Decision
- NEE Buy
- GILD Buy
- Analyst Count
- NEE 10
- GILD 23
- Target Price
- NEE $87.60
- GILD $116.36
- AVG Volume (30 Days)
- NEE 9.4M
- GILD 5.9M
- Earning Date
- NEE 10-22-2025
- GILD 11-05-2025
- Dividend Yield
- NEE 3.20%
- GILD 2.78%
- EPS Growth
- NEE N/A
- GILD 496.80
- EPS
- NEE 2.87
- GILD 5.01
- Revenue
- NEE $25,899,000,000.00
- GILD $28,863,000,000.00
- Revenue This Year
- NEE $15.46
- GILD $2.07
- Revenue Next Year
- NEE $9.70
- GILD $3.95
- P/E Ratio
- NEE $24.67
- GILD $22.69
- Revenue Growth
- NEE 0.19
- GILD 3.81
- 52 Week Low
- NEE $61.72
- GILD $81.83
- 52 Week High
- NEE $86.10
- GILD $121.83
- Technical
- Relative Strength Index (RSI)
- NEE 43.53
- GILD 48.34
- Support Level
- NEE $69.77
- GILD $110.15
- Resistance Level
- NEE $72.49
- GILD $114.13
- Average True Range (ATR)
- NEE 1.38
- GILD 2.28
- MACD
- NEE -0.14
- GILD -0.31
- Stochastic Oscillator
- NEE 42.90
- GILD 43.59
About NEE NextEra Energy Inc.
NextEra Energy's regulated utility, Florida Power & Light, is the largest rate-regulated utility in Florida. The utility distributes power to over 6 million customer accounts in Florida and owns 36 gigawatts of generation. FP&L contributes roughly 70% of NextEra's consolidated operating earnings. NextEra Energy Resources, the renewable energy segment, generates and sells power throughout the United States and Canada with more than 37 GW of generation capacity, including natural gas, nuclear, wind, and solar.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).